Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Change in Account Payables (2019 - 2025)

Korro Bio (KRRO) has disclosed Change in Account Payables for 6 consecutive years, with -$2.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables fell 1152.4% year-over-year to -$2.9 million, compared with a TTM value of -$2.3 million through Sep 2025, down 210.9%, and an annual FY2024 reading of -$1.3 million, down 143.26% over the prior year.
  • Change in Account Payables was -$2.9 million for Q3 2025 at Korro Bio, down from $1.1 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.8 million in Q4 2023 and bottomed at -$2.9 million in Q3 2025.
  • Average Change in Account Payables over 5 years is -$23789.5, with a median of -$202000.0 recorded in 2023.
  • The sharpest move saw Change in Account Payables surged 1128.71% in 2024, then plummeted 1152.4% in 2025.
  • Year by year, Change in Account Payables stood at -$382000.0 in 2021, then surged by 439.27% to $1.3 million in 2022, then skyrocketed by 115.35% to $2.8 million in 2023, then tumbled by 121.68% to -$605000.0 in 2024, then plummeted by 374.05% to -$2.9 million in 2025.
  • Business Quant data shows Change in Account Payables for KRRO at -$2.9 million in Q3 2025, $1.1 million in Q2 2025, and $99000.0 in Q1 2025.